SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-007361
Filing Date
2022-02-28
Accepted
2022-02-28 07:46:39
Documents
14
Period of Report
2022-02-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 Q4'21 8-K/PR alxo-8k_20220228.htm   iXBRL 8-K 40001
2 EX-99.1 alxo-ex991_6.htm EX-99.1 272109
3 GRAPHIC gerappfhwdnu000001.jpg GRAPHIC 27266
  Complete submission text file 0001564590-22-007361.txt   494854

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA alxo-20220228.xsd EX-101.SCH 5705
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE alxo-20220228_lab.xml EX-101.LAB 19410
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alxo-20220228_pre.xml EX-101.PRE 11588
8 EXTRACTED XBRL INSTANCE DOCUMENT alxo-8k_20220228_htm.xml XML 3560
Mailing Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-466-7125
ALX ONCOLOGY HOLDINGS INC (Filer) CIK: 0001810182 (see all company filings)

IRS No.: 850642577 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39386 | Film No.: 22683939
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences